CN Mobile Logo

Search form


Leukemia & Lymphoma

Leukemia & Lymphoma

Chronic infection with hepatitis B or C virus was associated with an increased risk for non-Hodgkin lymphoma among patients with HIV who are on antiretroviral therapy.

Maintenance therapy with norethandrolone significantly improved survival in elderly patients with acute myeloid leukemia without increasing toxicity.

An analysis of tyrosine kinase inhibitor initiation and adherence in Medicare beneficiaries with chronic myeloid leukemia suggests that out-of-pocket costs may be a barrier to treatment.

Frontline intensive therapy with rituximab plus high-dose sequential chemotherapy did not improve outcomes for high-risk patients with DLBCL compared with treatment with R-CHOP-14.

Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.

In this article we review the scientific rationale, preclinical evidence, and most recent clinical data for the use of checkpoint inhibitor therapy in patients with relapsed Hodgkin lymphoma.

Identification of effective lymphodepletion strategies, optimization of patient selection, and management of novel toxicities remain challenges in the growing field of cellular immunotherapy.


Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.